Answers are grounded in this paper and cite their sources.
Objective: The Low Biologically Available Glucose (LoBAG) diet was designed to improve glycemic control of type 2 diabetes mellitus (T2D). We evaluate changes in the gut microbiome when participants with T2D are given the LoBAG diet. Methods: Thirty-six participants with T2D taking metformin or no glucose-lowering medication were enrolled in a 12-week randomized controlled trial. Participants were randomly assigned to the LoBAG diet (30% low-starch carbohydrate, 30% protein, 40% fat) or a control diet (50% carbohydrate, 15% protein, 35% fat). Fecal samples were collected at weeks 0, 6, and 12 along with the primary outcome, hemoglobin A1c (HbA1c). Results: Diet groups were significantly distinct in terms of Bray-Curtis dissimilarity in weeks 6 and 12 following the dietary intervention (p<0.001, PERMANOVA), indicating shifts in the microbiome profile following the diet intervention. In particular, abundance of Firmicutes was lower in the LoBAG diet group (Mann-Whitney U test, p < 0.001). The primary outcome, HbA1c, was significantly more reduced in the LoBAG diet group (t-test, p=0.04, week 12 - baseline) following dietary intervention. Conclusions: Participants with T2D consuming the LoBAG diet had greater reduction in HbA1c over 12 weeks than those consuming a control diet. This difference was also associated with shifts in the gut microbiome, but further studies are needed to explore a relationship between HbA1c and the gut microbiome.
No takes yet. Share an insight, caveat, or question.
HOOPS et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: